Pharmacokinetics and pharmacodynamics of prasugrel versus clopidogrel in Chinese volunteers with different CYP2C19 genotypes

Trial Profile

Pharmacokinetics and pharmacodynamics of prasugrel versus clopidogrel in Chinese volunteers with different CYP2C19 genotypes

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2011

At a glance

  • Drugs Clopidogrel; Prasugrel
  • Indications Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Congenital heart defects; Embolism and thrombosis; Ischaemic heart disorders; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris
  • Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
  • Sponsors Daiichi Sankyo Inc; Eli Lilly
  • Most Recent Events

    • 05 Aug 2011 New trial record
    • 21 Jun 2011 Results published in the British Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top